Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Cescon

Showing results (91-100 of 133) with videos related to

Pageof 14
Sort By:
International Journal of Molecular Sciences|July 29, 2023
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase InhibitorsJesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
NPJ Breast Cancer|June 26, 2026
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse eventsHope S Rugo, David W Cescon, Peter Schmid, et al.
The New England Journal of Medicine|January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast CancerSara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2023
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast CancerDavid W Cescon, John Hilton, Serafin Morales Murilo, et al.
Current Oncology (Toronto, Ont.)|April 27, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Aalok Kumar, Katarzyna J Jerzak, Karen A Gelmon, et al.
Science Advances|September 7, 2022
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER<sup>+</sup> breast cancer with mitotic aberrationsIsabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, et al.
Molecular Cancer Therapeutics|July 31, 2019
Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and PolyploidyLin Zheng, Zibo Chen, Masanori Kawakami, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025Sandeep Sehdev, Anil Abraham Joy, Jean-François Boileau, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic SettingMita Manna, Karen A Gelmon, Jean-François Boileau, et al.
Pageof 14

Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
International Journal of Molecular Sciences|July 29, 2023
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase InhibitorsJesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
NPJ Breast Cancer|June 26, 2026
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse eventsHope S Rugo, David W Cescon, Peter Schmid, et al.
The New England Journal of Medicine|January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast CancerSara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2023
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast CancerDavid W Cescon, John Hilton, Serafin Morales Murilo, et al.
Current Oncology (Toronto, Ont.)|April 27, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Aalok Kumar, Katarzyna J Jerzak, Karen A Gelmon, et al.
Science Advances|September 7, 2022
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER<sup>+</sup> breast cancer with mitotic aberrationsIsabel Soria-Bretones, Kelsie L Thu, Jennifer Silvester, et al.
Molecular Cancer Therapeutics|July 31, 2019
Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and PolyploidyLin Zheng, Zibo Chen, Masanori Kawakami, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025Sandeep Sehdev, Anil Abraham Joy, Jean-François Boileau, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic SettingMita Manna, Karen A Gelmon, Jean-François Boileau, et al.
Pageof 14